Another Ranbaxy Drug Plant Fails FDA Test

Law360, New York (January 23, 2014, 7:24 PM EST) -- The U.S. Food and Drug Administration on Thursday barred drug products from a Ranbaxy Laboratories Inc. manufacturing plant in India from the U.S. market, the sixth company facility found to fail good manufacturing standards.

The FDA prohibited Ranbaxy's Toansa, India, site from manufacturing active pharmaceutical ingredients for FDA-regulated products after officials uncovered "significant" violations of U.S.-promulgated manufacturing practices meant to ensure drug safety.

Topping the list was Ranbaxy employees’ practice of retesting raw materials, intermediate drug products and finished APIs that failed to meet specifications until...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.